Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein pathways provide clues in leukemia research

01.06.2012
Rice, MD Anderson scientists hope detailing networks will help fine-tune therapies
Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

Their research involved the creation of a new computational approach to identifying complex networks in protein signaling. They reported their work this month in the journal Proteomics.

With their new method, Rice bioengineer Amina Qutub, MD Anderson clinician and scientist Steven Kornblau and Rice graduate student Heather York analyzed more than a decade’s worth of data. They identified patterns in the expression of 203 proteins studied in cells of acute myeloid leukemia (AML) patients and found nearly 700 protein pairs (from among thousands of possibilities) implicated in such networks.

The goal is to fine-tune therapy for patients, Qutub said. If it’s possible to know the protein signaling pathways of particular types of leukemia, she said, then drugs may be found – or designed – to target the disease by blocking those pathways.

“Leukemia is not just one disease,” said Qutub, who attended Rice as an undergraduate and is now an assistant professor of bioengineering based at Rice’s BioScience Research Collaborative. “It’s many, many diseases lumped into one category. You can’t use a sledgehammer approach to treat it, though that’s what clinicians have been doing.”

“A Phillips head screwdriver does great if you’ve got a cross on your screw head,” Kornblau said. “It doesn’t work very well if you’ve got a slot. Companies have drugs that might work gangbusters in a small fraction of patients, but if you study a large aggregate, it doesn’t look like a very active agent. Ideally, if it works in 5 percent of patients and you can pick them out ahead of time, you put them on the right drug and spare the other 95 percent from getting a drug that is not going to help them.”

It’s not unusual for leukemia patients to go into remission, Qutub said, but most suffer a relapse within two years. “We’re trying to figure out what’s so different about these patients, and whether we can enhance their therapy. The only way we know to do that is to figure out the protein signature.”

Proteins are the workhorses of the cell. Created from blueprints stored in DNA, they pass chemical signals from one to another with instructions on just about every activity a cell is capable of. But when their basic coding is scrambled, they can just as easily cause a cell to self-destruct.

Qutub likened protein signaling pathways to city traffic. “You might take a train, drive a car, walk or take a bicycle, but eventually you would get to your location,” she said. “In cancer patients, protein pathways seem to follow patterns. In normal cells, there are predominant pathways, and while you may have the same pathways in cancer cells, they might also have alternate routes – and take them, to varying degrees.”

Specific routes proteins use to pass signals may be the key to determining their type, so it was worth investigating a treasure trove of data that had been gathered from MD Anderson patients, Qutub said.

The project began with a chance meeting by Qutub and Kornblau at a conference in Colorado on hypoxia. “Steve said, ‘You’re working with mathematical modeling of hypoxic response. I have a patient set I think you might be interested in.’ That’s how it started, and it took us down a very different road, using machine-learning algorithms and statistical techniques that hadn’t been part of my core research but have now become integral to both this project and other research in the lab,” Qutub said.

The World Health Organization had categorized AML patients by certain cell phenotypes, Qutub said, “but very little had been done at the protein level. Our clinical collaborators had started genetic and proteomic studies a while back and identified recurrent patterns of protein expression, some of which were associated with recurrent chromosomal changes like ‘inv (16),’ the inversion of chromosome 16, or ‘t(8;21),’ which is the transpose of the 8 and 21 chromosomes.” They are found in about 15 percent of patients with AML, she said.

“Patients with these two chromosomal changes respond more favorably to current AML therapy,” Kornblau said, “and the genes from each of these genetic abnormalities are involved in the same transcription factor complex, creating a mechanistic link. But despite this mechanistic link, they differ in some clinical features and outcome.”

Kornblau’s data was precisely what Qutub and her group needed. They targeted inv (16) and t(8;21) to learn what protein pathways were common to both of these cytogenetic categories, what might explain their increased responsiveness and what changes were unique to each that might explain their clinical differences. From the mass of data – more than 20,000 possible protein pairs – they found that 678 pairs related to inv (16) and t(8;21) were significantly different compared with normal cells.

“There are some genetic markers that are definitely associated with a prognosis of leukemia,” Qutub said. “And other things can cause leukemia — acute myeloid in particular — perhaps even chemotherapy itself. The way cancer patients are treated may be causing mutations and in turn triggering leukemic response.”

With their analytical method tried and tested, Qutub and her team can now statistically group patients who present with particular protein pathways by age, gender, therapies and other criteria, and then take a closer look at protein signaling pathways in bone marrow-derived stem cells, a prime suspect in patients who relapse even after decades of remission. “We think something has to be unique about stem cells,” she said.

The key problem with all cancers, including leukemia, is their plasticity, she said. “Cancer has multiple ways of getting to the same destination. You try one drug, and cancer’s going to circumvent you and go a different way. What we’re trying to say is, ‘Here are all the possible ways,’ so we can begin to target the intersections.”

The research was supported by the Leukemia and Lymphoma Society and Rice University.

Related links:

Read the abstract at http://onlinelibrary.wiley.com/doi/10.1002/pmic.201100491/abstract

Qutub Lab: http://www.qutublab.rice.edu/

BioScience Research Collaborative: http://brc.rice.edu/home/

Image for download:
http://news.rice.edu/wp-content/uploads/2012/05/HighwayMaps_Proteomics.jpg

New research by scientists at Rice University and the University of Texas MD Anderson Cancer Center profiles protein pathways distinctive to certain leukemia patients. The graphic shows interacting proteins in leukemia cells that can be characterized by networks analogous to highways. (Qutub Lab/Rice University)


Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is known for its “unconventional wisdom.” With 3,708 undergraduates and 2,374 graduate students, Rice’s undergraduate student-to-faculty ratio is 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice has been ranked No. 1 for best quality of life multiple times by the Princeton Review and No. 4 for “best value” among private universities by Kiplinger’s Personal Finance. To read “What they’re saying about Rice,” go to www.rice.edu/nationalmedia/Rice.pdf

David Ruth | EurekAlert!
Further information:
http://www.rice.edu/nationalmedia/Rice.pdf

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

A new dead zone in the Indian Ocean could impact future marine nutrient balance

06.12.2016 | Earth Sciences

Significantly more productivity in USP lasers

06.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>